WO1999005304A1 - Genetically engineered rhodococcus vaccine - Google Patents
Genetically engineered rhodococcus vaccine Download PDFInfo
- Publication number
- WO1999005304A1 WO1999005304A1 PCT/US1998/015911 US9815911W WO9905304A1 WO 1999005304 A1 WO1999005304 A1 WO 1999005304A1 US 9815911 W US9815911 W US 9815911W WO 9905304 A1 WO9905304 A1 WO 9905304A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vapa
- bacteria
- vaccine
- rhodococcus
- equi
- Prior art date
Links
- 241000316848 Rhodococcus <scale insect> Species 0.000 title claims abstract description 45
- 229960005486 vaccine Drugs 0.000 title claims description 73
- 241000158504 Rhodococcus hoagii Species 0.000 claims abstract description 102
- 238000000034 method Methods 0.000 claims abstract description 72
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 42
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 42
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 42
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims abstract description 39
- 230000003053 immunization Effects 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 16
- 101150047903 vapA gene Proteins 0.000 claims description 128
- 241000894006 Bacteria Species 0.000 claims description 125
- 239000012634 fragment Substances 0.000 claims description 51
- 230000002163 immunogen Effects 0.000 claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 35
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 16
- 210000003205 muscle Anatomy 0.000 claims description 15
- 241000283086 Equidae Species 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 241000283073 Equus caballus Species 0.000 claims description 13
- 230000010076 replication Effects 0.000 claims description 13
- 230000001105 regulatory effect Effects 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 206010065041 Rhodococcus infection Diseases 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001131 transforming effect Effects 0.000 claims description 3
- 241000282887 Suidae Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 31
- 210000002540 macrophage Anatomy 0.000 description 52
- 239000013612 plasmid Substances 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 46
- 108020004414 DNA Proteins 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 43
- 230000014509 gene expression Effects 0.000 description 31
- 108091007433 antigens Proteins 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 239000000427 antigen Substances 0.000 description 27
- 230000012010 growth Effects 0.000 description 24
- 238000002649 immunization Methods 0.000 description 23
- 108010065805 Interleukin-12 Proteins 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 19
- 230000003834 intracellular effect Effects 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 17
- 230000001018 virulence Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 14
- 230000024932 T cell mediated immunity Effects 0.000 description 13
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 12
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 8
- 230000001681 protective effect Effects 0.000 description 8
- 241000701022 Cytomegalovirus Species 0.000 description 7
- 102000008070 Interferon-gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 229940044627 gamma-interferon Drugs 0.000 description 7
- 230000001900 immune effect Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000013605 shuttle vector Substances 0.000 description 7
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000010240 RT-PCR analysis Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 5
- 108091061960 Naked DNA Proteins 0.000 description 5
- 210000003578 bacterial chromosome Anatomy 0.000 description 5
- 229960003150 bupivacaine Drugs 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000004727 humoral immunity Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000000411 inducer Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000003278 mimic effect Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 241000186359 Mycobacterium Species 0.000 description 3
- 241000187654 Nocardia Species 0.000 description 3
- 241000714474 Rous sarcoma virus Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000003505 Myosin Human genes 0.000 description 2
- 108060008487 Myosin Proteins 0.000 description 2
- 101000783356 Naja sputatrix Cytotoxin Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 241000187694 Rhodococcus fascians Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000002340 cardiotoxin Substances 0.000 description 2
- 231100000677 cardiotoxin Toxicity 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 229960003624 creatine Drugs 0.000 description 2
- 239000006046 creatine Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000008073 immune recognition Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- GMKMEZVLHJARHF-UHFFFAOYSA-N (2R,6R)-form-2.6-Diaminoheptanedioic acid Natural products OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 241000713826 Avian leukosis virus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101000653197 Beet necrotic yellow vein virus (isolate Japan/S) Movement protein TGB3 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 108010058432 Chaperonin 60 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000203751 Gordonia <actinomycete> Species 0.000 description 1
- 241000203749 Gordonia bronchialis Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000987946 Jensenia <liverwort> Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000056189 Neutrophil collagenases Human genes 0.000 description 1
- 108030001564 Neutrophil collagenases Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010058556 Serositis Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 101150057950 aph gene Proteins 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000009058 cervical adenitis Diseases 0.000 description 1
- 208000012751 cervical lymphadenitis Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 108010089843 gamma delta resolvase Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 101150062015 hyg gene Proteins 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000010453 mesenteric lymphadenitis Diseases 0.000 description 1
- GMKMEZVLHJARHF-SYDPRGILSA-N meso-2,6-diaminopimelic acid Chemical compound [O-]C(=O)[C@@H]([NH3+])CCC[C@@H]([NH3+])C([O-])=O GMKMEZVLHJARHF-SYDPRGILSA-N 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000001446 muramyl group Chemical group N[C@@H](C=O)[C@@H](O[C@@H](C(=O)*)C)[C@H](O)[C@H](O)CO 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Inorganic materials [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UBCKGWBNUIFUST-YHYXMXQVSA-N tetrachlorvinphos Chemical compound COP(=O)(OC)O\C(=C/Cl)C1=CC(Cl)=C(Cl)C=C1Cl UBCKGWBNUIFUST-YHYXMXQVSA-N 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to methods and compositions for immunizing a vertebrate against Rhodococcus infection, and to methods for expressing recombinant nucleic acids in Rhodococcus.
- Rhodococcus are gram-positive, aerobic, non-sporulating, partially acid-fast Actinomycetes, which were formerly classified as Nocardia, Mycobacterium, Gordona, Jensenia, or in the "rhodochrous" complex.
- Nocardia, Corynebacteria and Mycobacterium are closely related to Rhodococcus, each exhibiting nocardioform morphology, having mycolic acids, meso-diaminopimelic acid, arabinose and galactose in their cell walls and having a high G+C content ( > 59 mol %) in their cellular DNA.
- Rhodococcus species are common in soil, and inhalation of dust is believed to be a primary mechanism of infection in both animals and man.
- pathogenic species include R. fascians, a plant pathogen, R. bronchialis , a human pathogen, and R. equi, an animal pathogen.
- Rhodococcus equi (R. equi, formerly called Corynebacterium equi) is a facultative intracellular bacterium that is one of the leading causes of pneumonia in young horses (foals). Rhodococcus equi, which is endemic on some horse farms, can cause extensive morbidity and mortality. Rhodococcal disease occurs primarily in foals under six months of age, with the majority of cases occurring in foals under three months of age. R. equi generally does not cause pneumonia in older horses because they are able to mount an effective immune response, but the organism can cause disease in older animals that are imrnunocompromised or have other systemic illnesses. At one veterinary institution, R.
- R. equi pneumonia can be insidious in nature, and consequently is often quite advanced at the time of clinical recognition. Because of its insidious nature, treatment of the pneumonia typically necessitates long term antimicrobial therapy which is very costly and not always effective. Even when the therapy is effective, protracted pulmonary disease can affect the eventual performance of the adult horse. R. equi also causes chronic cervical lymphadenitis in swine.
- R. equi Although R. equi is not generally considered pathogenic in humans, it can cause infection and even death in AIDS patients and in individuals who are otherwise imrnunocompromised. The primary manifestation of R. equi infection in humans, as in foals, is pneumonia. B) Virulence of R. equi
- Tan et al. demonstrated that R. equi produce three antigenically-related virulence-associated proteins: a diffuse 18-22 kDa protein, a 17.5 kDa protein, and a 15 kDa protein (Can. J. Vet. Res. 59:51-59 (1995)).
- a single gene was cloned and shown to encode all three proteins, the molecular weight differences apparently being due to lipid modification. This gene was designated vapA, its protein product was designated VapA.
- Humoral immunity involves antibodies, proteins which are secreted into the body fluids and which directly recognize an antigen.
- the cellular system in contrast, relies on special cells which recognize and kill other cells which are producing foreign antigens. This basic functional division reflects two different strategies of immune defense.
- Humoral immunity is mainly directed at antigens which are exogenous to the animal whereas the cellular system responds to antigens which are actively synthesized within the animal.
- Antibody molecules the effectors of humoral immunity, are secreted by special B lymphoid cells, B cells, in response to antigen.
- Antibodies can bind to and inactivate antigen directly (neutralizing antibodies) or can activate other cells of the immune system to destroy the antigen.
- cytotoxic T lymphocytes CTLs
- CTLs cytotoxic T lymphocytes
- MHC major histocompatibility complex
- Essentially all nucleated cells have class I molecules. It is believed that proteins produced within the cell are continually degraded to peptides as part of normal cellular metabolism. These fragments are bound to the MHC molecules and transported to the cell surface.
- the cellular immune system constantly monitors the spectra of proteins produced in all cells in the body and is poised to eliminate any cells producing foreign antigens.
- the cellular immune response also involves helper T cells which produce cytokines and thereby elicit participation of additional immune system cells.
- Immunization which comprises the administration of a vaccine in order to induce an immune response, is a method for preparing an animal to respond to an antigen. Immunization is more complex than immune recognition and involves not only B cells and cytotoxic T cells but other types of lymphoid cells as well. During immunization, cells which recognize the antigen (B cells or cytotoxic T cells) are clonally expanded. In addition, the population of ancillary cells (helper T cells) specific for the antigen increases. Immunization also involves specialized antigen presenting cells which can process an antigen and display it in a form which can stimulate one of the pathways of the immune system.
- Macrophages are active secretory cells which can exert an influence on the developing immune response by producing immunomodulatory cytokines.
- cytokines One of the important cytokines that is made by macrophages is IL-12.
- This cytokine has been identified as a key determinant in the generation of cell- mediated immunity (Trinchieri and Gerosa, J. Leukocyte Biol. 59:505-511 (1996)). Animals treated with antibody to IL-12 fail to develop cell mediated immunity to intracellular pathogens (Id.). Conversely, susceptible animals treated with recombinant IL-12 develop resistance to infection with intracellular pathogens (Heinzel et al. , J. Exp. Med. 177: 1505-1512 (1993).
- IL-12 has been used as an adjuvant to specifically elicit cell-mediated immunity (Miller et al. , J. Immunol. 155:4817-4828 (1995)).
- Rhodococcus Genetic systems for the transformation of Rhodococcus are still in the developmental phase. Several groups have transformed Rhodococcus and related nocardia. Desomer and colleagues used electroporation to transform Rhodococcus fascians with a fragment of an indigenous Rhodococcus plasmid conferring chloramphenicol resistance (Desomer et al. , Mol. Micro. 5:2115-2124 (1991)). Vectors comprising indigenous Rhodococcus plasmid origins of replication are described in U.S. Patent Nos. 5,246,857 and 4,920,054. Quan and Dabbs recently transformed Rhodococcus with an arsenic resistance cloning vector (Quann and Dabbs, Plasmid 29:74-79 (1993)).
- the present invention is based upon the surprising discovery that an avirulent strain of R. equi, transformed with a gene encoding the virulence- associated VapA protein, is not virulent.
- the invention is further based upon the discovery that the transformed strain is a potent inducer of IL-12, an important component of cell mediated immunity, and that the transformed strain can induce protective immunity in animals.
- the present invention therefore relates to the discovery of safe and effective methods and compositions for immunizing a vertebrate against Rhodococcus infection and against the pneumonia associated with R. equi infection.
- the invention provides a method of immunizing a vertebrate against Rhodococcus comprising administering a vaccine to the vertebrate, wherein said vaccine comprises a nucleic acid encoding the R. equi VapA protein or an immunogenic fragment thereof.
- the vertebrate is a mammal; in a more preferred embodiment the vertebrate is selected from the group consisting of pigs, horses, and humans; in a most preferred embodiment the vertebrate is a horse. Where the vertebrate is a horse the horse is preferably a foal.
- nucleic acid encoding the R. equi VapA protein or an immunogenic fragment thereof is DNA.
- the DNA encoding VapA or an immunogenic fragment thereof is operatively linked to regulatory sequences.
- the vaccine further comprises a pharmaceutically acceptable carrier.
- the vaccine comprises recombinant bacteria which express the DNA encoding VapA or an immunogenic fragment thereof.
- the DNA encoding VapA or an immunogenic fragment thereof may be extrachromosomal or may be integrated into the bacterial chromosome.
- the bacteria further express an immunostimulatory cytokine.
- the recombinant bacteria which express the DNA encoding VapA or an immunogenic fragment thereof are an avirulent strain of Rhodococcus. In a most preferred embodiment the recombinant bacteria which express the DNA encoding VapA or an immunogenic fragment thereof are an avirulent strain of R. equi.
- the recombinant bacteria which express the DNA encoding VapA or an immunogenic fragment thereof are
- BCG Bacillus Calmette-Guerin
- the vaccine comprises a pharmaceutically acceptable carrier and DNA encoding VapA or an immunogenic fragment thereof.
- the DNA vaccine is administered to the vertebrate by injection. In some embodiments the vaccine is administered to the vertebrate by a gene gun. In a preferred embodiment the vaccine is administered into muscle or skin; in a most preferred embodiment the vaccine is administered into muscle.
- This invention further provides a composition
- a composition comprising a pharmaceutically acceptable carrier and recombinant bacteria which express DNA encoding VapA or an immunogenic fragment thereof.
- the DNA encoding VapA or an immunogenic fragment thereof may be extrachromosomal or may be integrated into the bacterial chromosome.
- the recombinant bacteria are an avirulent strain of Rhodococcus; in a most preferred embodiment the recombinant bacteria are an avirulent strain of/?, equi.
- the recombinant bacteria are Mycobacteria; in a most preferred embodiment the recombinant bacteria are BCG.
- the recombinant bacteria also express an immunostimulatory cytokine.
- the invention also provides a method for expressing a recombinant nucleic acid of interest in Rhodococcus cells comprising:
- the recombinant vector further comprises an E. coli origin of replication.
- the recombinant nucleic acid encodes a polypeptide of interest; in a more preferred embodiment the polypeptide of interest is recovered from the transformed cells.
- the invention also provides a method of inducing an immune response in a vertebrate comprising administering recombinant Rhodococcus bacteria which express DNA encoding an immunogen.
- the DNA encoding the immunogen may be extrachromosomal or may be integrated into the bacterial chromosome.
- the recombinant bacteria also express an immunostimulatory cytokine.
- the recombinant bacteria are R. equi.
- the invention encompasses a method of preventing Rhodococcus infection in a vertebrate comprising administering a vaccine to the vertebrate, wherein said vaccine comprises a nucleic acid encoding the R. equi VapA protein or an immunogenic fragment thereof, as well as a method of preventing pneumonia associated with Rhodococcus infection in a vertebrate comprising administering a vaccine to the vertebrate, wherein said vaccine comprises a nucleic acid encoding the R. equi VapA protein or an immunogenic fragment thereof.
- the vertebrate is a horse; in a most preferred embodiment the vertebrate is a foal.
- the invention also encompasses the use of a nucleic acid encoding the R. equi VapA protein or an immunogenic fragment thereof for the preparation of a vaccine against Rhodococcus.
- Figure 1 shows the growth of virulence-associated plasmid-positive (103 + , closed circles) and plasmid-negative (103-, open circles) strains of R. equi in murine macrophages. Growth is expressed as the number of bacteria per 200 macrophages (1A) or the number of macrophages (out of 200) with 10 or more bacteria in them (IB).
- Figure 2 shows the growth of virulence-associated plasmid-positive (103 + , triangles) and plasmid-negative (103-, circles) strains of R. equi in mice.
- Figure 3 shows flow cytometry profiles of VapA expression in R. equi 103 + (3A), 103 " pYUB415 (3B), and 103 " pYUB415-VapA (3C).
- Figure 4 shows the growth of R. equi in the macrophage-like cell line J774. Growth is expressed as the number of bacteria per 200 macrophages (4A) or the number of macrophages (out of 200) with ten or more bacteria in them (4B).
- Figure 5 shows the growth of 103 + (squares), 103-415 (vector alone, triangles), and 103-VapA2 (103 " transformed with pYUB415-VapA, circles) R. equi in mice.
- Figure 6 shows RT-PCR detection of IL-12 and iNOS mRNA.
- Figure 7 shows the growth of R. equi strains in the liver (7 A) and spleen (7B) of vaccinated mice.
- R. equi bacteria transformed with a gene (vapA) expressing VapA protein are not virulent, and that avirulent strains of R. equi are potent inducers of IL-12 by macrophages.
- the present invention provides methods and compositions for immunizing a vertebrate against Rhodococcus infection, and for preventing pneumonia associated with R. equi infection.
- the invention further relates to methods for expressing recombinant nucleic acids in Rhodococcus cells.
- “Expression” means the realization of genetic information encoded by a nucleic acid to produce a functional RNA or protein.
- Immune response means a cytotoxic T cell response or increased serum levels of antibodies to an antigen, or to the presence of neutralizing antibodies to an antigen such as a Rhodococcus protein. Immune response includes "protective immunity, " which is the ability of the serum antibodies and/or cytotoxic T cell response to totally or partially protect against disease caused by an infectious agent such as Rhodococcus.
- Immunize refers to the act of inducing an immune response.
- Immunogenic fragment means a fragment of a polypeptide which is capable of inducing an immune response.
- “Operatively linked to regulatory sequences” means that the polypeptide coding region is connected to transcriptional and translational regulatory sequences in such a way as to permit polypeptide expression when the appropriate molecules (such as activator proteins and polymerases) are present in a cell or cell free system.
- Vaccine means any composition which is administered in order to induce an immune response.
- Vaccines according to the present invention comprise a nucleic acid encoding VapA or an immunogenic fragment thereof.
- One embodiment of the present invention is directed to the use of a vaccine comprising recombinant bacteria expressing VapA; another embodiment is directed to the use of a vaccine comprising naked DNA.
- the vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof (including recombinant bacteria embodiments and naked DNA embodiments) may be administered to various tissues and cells of the animal body, including muscle, skin, brain, lung, liver, spleen, and blood.
- Routes of administration include but are not limited to intramuscular, intraperitoneal, intradermal, subcutaneous, intravenous, intraarterial, intraocular, and oral, as well as transdermal, and by inhalation or suppository.
- Administration of the vaccine is preferably by means of parenteral administration to the cells of muscle or skin.
- the vaccine may be injected into muscle or skin using an injection syringe or a needleless injection device.
- the vaccine may also be delivered into muscle or skin using a gene gun.
- immunization comprises a single administration of the vaccine.
- the vaccine is administered at least twice over a period of time.
- the period of time between immunizations may include from 24 hours apart to two weeks or longer.
- at least two and up to four or more separate immunizations are given simultaneously at different sites.
- the vaccine comprising the nucleic acid encoding VapA or an immunogenic fragment thereof includes a pharmaceutically acceptable carrier.
- Pharmaceutically acceptable carriers include but are not limited to saline, buffered saline, isotonic saline (e.g.
- compositions are preferably sterile and pyrogen free.
- stabilizers such as gelatin or albumin, may be included in the composition.
- the vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof may optionally be formulated with one or more response enhancing agents such as: compounds which enhance transfection, compounds which stimulate cell division, compounds which stimulate immune cell migration to the site of administration (inflammatory agents), compounds which enhance an immune response (adjuvants), or compounds having two or more of these activities.
- response enhancing agents such as: compounds which enhance transfection, compounds which stimulate cell division, compounds which stimulate immune cell migration to the site of administration (inflammatory agents), compounds which enhance an immune response (adjuvants), or compounds having two or more of these activities.
- Response enhancing agents include but are not limited to lectins, growth factors, cytokines and lymphokines such as ⁇ -interferon, ⁇ -interferon, platelet derived growth factor (PDGF), G-CSF, GM-CSF, TNF, epidermal growth factor (EGF), IL-1, IL-2, IL-4, IL-8, IL-10 and IL-12 as well as collagenase, fibroblast growth factor, estrogen, dexamethasone, saponins, surface active agents such as immune-stimulating complexes (ISCOMS), Freund's incomplete adjuvant, LPS analog including monophosphoryl Lipid A (MPL), muramyl peptides, quinone analogs and vesicles such as squalene and squalane, hyaluronic acid and hyaluronidase.
- the vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof may also include or express additional antigens against which protective immunity is
- the vaccine may be administered to foals or to newborn horses on farms with endemic R. equi.
- the vaccine may also be administered to foals or to newborn horses on farms without endemic R. equi, i.e. , prophylactically.
- One preferred embodiment of the present invention is a vaccine comprising recombinant bacteria expressing VapA or an immunogenic fragment thereof.
- the VapA may be expressed from the vapA gene which is either extrachromosomal or integrated into the bacterial chromosome.
- the vaccine compositions according to this embodiment contain about 1 x 10 5 to about 1 x 10 10 bacteria. In a preferred embodiment about 1 x 10 6 to about 1 x 10 8 bacteria are administered in each immunization. In a more preferred embodiment about 5 x 10 6 to about 5 x 10 7 bacteria are administered, and in a most preferred embodiment about 1 x 10 7 bacteria are administered in each immunization.
- the recombinant bacteria are an avirulent strain of Rhodococcus equi.
- the inventor has shown that avirulent strains of R. equi are potent inducers of IL-12 from macrophages. IL-12 stimulates cell-mediated immunity, the component of the immune system most important for R. equi clearance, and the part that is most affected in AIDS patients. R. equi is therefore expected to be an excellent vaccine vector, especially where it is important to stimulate cell mediated immunity.
- the recombinant bacteria are the relatively avirulent mycobacterium called BCG (Bacillus Calmette-Guerin).
- BCG is antigenically similar to Mycobacterium tuberculosis, it is routinely used to vaccinate humans in Eastern European and Asian countries against tuberculosis. In fact, BCG is one of the most widely used human vaccines. In the past 35 years it has been administered to over 2.5 billion people, with remarkably few adverse effects. Thus, BCG is considered to be "safe" as a vaccine vector. BCG can be given at birth and engenders long-lived immune responses after a single immunization. Recombinant BCG can be used to induce both humoral and cellular immunity.
- the VapA or immunogenic fragment thereof may be expressed from a stably integrated copy of all or part of the vapA gene or from an extrachromosomal copy of all or part of the vapA gene, using the methods described in U.S. Patent Nos. 5,504,005 and 5,591 ,632 which are inco ⁇ orated herein by reference.
- the BCG also express a secreted immunostimulatory cytokine which is believed to enhance the immune response.
- Immunostimulatory cytokines which may be expressed include but are not limited to interferons (including ⁇ , ⁇ , and ⁇ -interferon), the interleukins (including interleukins 1-12), tumor necrosis factors (including TNF and ⁇ ), and the colony stimulating factors (including M-CSF, G-CSF, and GM-CSF).
- interferons including ⁇ , ⁇ , and ⁇ -interferon
- the interleukins including interleukins 1-12
- tumor necrosis factors including TNF and ⁇
- colony stimulating factors including M-CSF, G-CSF, and GM-CSF.
- Another preferred embodiment of the present invention is a vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof.
- the nucleic acid can be DNA or RNA.
- the nucleic acid is naked DNA.
- DNA vaccines are delivered into mammalian cells where it is transcribed and translated into the VapA protein. This expressed protein then serves as the immunogen to elicit an immune response to R. equi.
- the immune response elicited by DNA vaccines is broad-based, including both humoral and cell mediated responses.
- the DNA comprises a cDNA encoding the entire VapA protein.
- the DNA encodes an immunogenic fragment of VapA.
- DNAs encoding fragments of VapA can be constructed using the techniques of recombinant DNA technology, which are known to those of ordinary skill in the art. General methods for the cloning and expression of recombinant molecules are described in Sambrook et al. Molecular Cloning, a Laboratory Manual 2d Ed. , Cold Spring Harbor Laboratories 1989), and in Ausubel (Current Protocols in Molecular Biology, Wiley and Sons, 1987), which are inco ⁇ orated herein by reference. The immunogenicity of a fragment can be tested using standard immunological methods and the techniques disclosed herein.
- the DNA encoding VapA or an immunogenic fragment thereof may be operatively linked to regulatory sequences which include promoters and polyadenylation signals.
- regulatory sequences include translation initiation signals (Kozak regions), termination codons, and enhancers.
- the regulatory sequences used must be functional within the cells of the vertebrate to be immunized.
- promoters examples include but are not limited to promoters from Simian Virus 40 (SV40), Mouse Mammary Tumor Virus (MMTV) promoter, Human Immunodeficiency Virus (HIV) such as the HIV Long Terminal Repeat (LTR) promoter, Moloney virus, ALV, Cytomegalovirus (CMV) such as the CMV immediate early promoter, Epstein Barr Virus (EBV), Rous Sarcoma Virus (RSV) as well as promoters from human genes such as human actin, human myosin, human hemoglobin, human muscle creatine and human metallothionein.
- the promoter is the CMV immediate early promoter, as described in U.S. Patent Nos.
- polyadenylation signals that can be used in the present invention include but are not limited to SV40 polyadenylation signals and LTR polyadenylation signals.
- enhancers may be selected from the group including but not limited to human Actin, human Myosin, human Hemoglobin, human muscle creatine and viral enhancers such as those from CMV, RSV and EBV.
- the regulatory sequences must be operably linked to the nucleic acid that encodes VapA. Accordingly, it is necessary for the initiation and termination codons to be in frame with the coding sequence.
- the vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof comprises a plasmid expression vector.
- the vaccine comprising a nucleic acid encoding VapA or an immunogenic fragment thereof comprises a self-amplifying replicon such as an alphaviral replicon (Berglund et al. , Nature Biotechnology 16:562-65 (1998)).
- Enhancing agents can be used to improve the efficiency of nucleic acid vaccines.
- Cardiotoxin is injected before the injection of the nucleic acid. This procedure has been shown to enhance the efficiency of gene transfer (Whalen et al. , Dev. Biol. 141:24-40 (1990)).
- bupivacaine or a related response enhancing agent, is administered prior to, simultaneously with or subsequent to the nucleic acid, as described in U.S. Patent No. 5,593,972 which is inco ⁇ orated herein by reference. Bupivacaine promotes and facilitates the uptake of genetic material by the cell, so administration of the nucleic acid in conjunction with bupivacaine facilitates entry of the genetic constructs into cells.
- Bupivacaine is believed to disrupt or otherwise render the cell membrane more permeable, and to stimulate cell division. Administration of bupivacaine also irritates and damages the tissue. As such, it acts as an inflammatory agent which elicits migration and chemotaxis of immune cells to the site of administration.
- the vaccine compositions according to this embodiment comprise about 1 nanogram to about 1000 micrograms of DNA. In some preferred embodiments, the vaccines comprise about 10 nanograms to about 800 micrograms of DNA. In some preferred embodiments, the vaccines comprise about 0.1 to about 500 micrograms of DNA. In some preferred embodiments, the vaccines comprise about 1 to about 350 micrograms of DNA. In some preferred embodiments, the vaccines comprise about 25 to about 250 micrograms of DNA. In some preferred embodiments, the vaccines comprise about 100 micrograms DNA.
- VapA, cytokines, or other proteins or peptides in a sample may be determined by contacting the sample with a polyclonal or monoclonal antibody which recognizes the molecule of interest.
- Methods for measuring protein expression include the "Western” blotting technique, fluorescence activated cell sorting (FACS), and enzyme-linked immunosorbent assays (ELISA).
- Polyclonal antibodies may be prepared by administering VapA, or a fragment, derivative, or epitope thereof, to an animal then harvesting antisera using techniques and procedures known in the art.
- Monoclonal antibodies may be prepared using methods which are well known to those of skill in the art. Briefly, VapA protein is used to immunize spleen cells of Balb/C mice. The immunized spleen cells are fused with myeloma cells. Fused cells containing spleen and myeloma cell characteristics are isolated by growth in HAT medium, a medium which kills both parental cells, but allows the fused products to survive and grow. The preparation of monoclonal antibodies specific for VapA (designated Mabl03) has been described (Tan et al. , Can. J. Vet. Res. 59:51-59 (1995)).
- mRNAs encoding cytokines or other gene products may be determined using the "Northern” blotting technique, RT-PCR (reverse transcription followed by polymerase chain reaction), or other methods known to those of skill in the art.
- the course of infection with R. equi is advantageously studied using mice as an animal model .
- the course of infection may be followed by measuring the number of bacteria in the liver, lung, and spleen over time, using a colony forming assay.
- Immunological parameters can also be examined in vaccinated mice, and these can be compared to control mice.
- Serum can be drawn from immunized animals to measure antibodies to Rhodococcus or to VapA.
- T cells are isolated from both the spleens and the lymph nodes of mice and exposed to either crude R. equi supernatants as a source of antigen, or to partially purified VapA.
- T cell proliferation is measured by the inco ⁇ oration of tritiated thymidine.
- the production of IL-4 and ⁇ -interferon by T cells from vaccinated mice is determined by RT-PCR (mRNA) and by ELISA (protein).
- macrophages are washed from the peritoneal cavity of mice at varying times post-vaccination. Biochemical and functional studies are performed on these cells.
- the transcription of the gene for the inducible form of nitric oxide synthetase (iNOS) is the best marker for macrophage activation in the murine system. Transcription of iNOS is analyzed using RT-PCR. The production of nitric oxide is measured by the Griess reagent. Functional assays can also be performed on these macrophages. The inventor has shown that virulent isolates of R. equi cannot survive in macrophages that have been activated in vitro by exposure to ⁇ -interferon.
- Macrophages from vaccinated mice are incubated with R. equi and the number of bacteria surviving after 48 hours is determined, and compared to macrophages from nonvaccinated mice. These molecular and functional criteria are used to determine the activation state of macrophages in vaccinated animals. These studies allow the optimization of the efficacy of each of the vaccine approaches.
- the level of protective immunity is advantageously quantitated by measuring clearance from the lung.
- Virulent R. equi are delivered via an aerosol route in order to mimic the natural route of infection.
- To aerosolize bacteria into the lungs of mice the mice are placed into a sealed container within a standard aerosol generator machine equipped with a venturi unit. This unit produces an aerosol mist of bacteria that the mice inhale.
- the suite in which the generator is placed is under negative pressure with respect to atmospheric pressure and all air leaving the room is HEPA filtered.
- the aerosol is generated by an ultrasonic nebulizer with a disposable drug vial (Hospital Medical Co. Montreal, Quebec, CA). Approximately 20 ml of solution containing from 1 x 10 7 to 1 x 10 9 bacteria/ml are placed into the vial which is attached to an inhalation mask. Foals are challenged for approximately 15 min with 10-20 ml of the suspension (Chirino- Treho et al. , Can. J. Vet. Research 51:444-47 (1987).
- animals are first immunized with a VapA vaccine and then increasing does of virulent bacteria are aerosolized into the lungs.
- the number of bacteria in the lung, liver, and spleen is quantitated over time.
- a recombinant nucleic acid of interest is expressed in Rhodococcus cells.
- the Rhodococcus cells are transformed with a vector which comprises the nucleic acid of interest and also a mycobacterial origin of replication.
- the vector further comprises a second origin of replication, which allows the vector to replicate in a microorganism such as E. coli, B. subtilis, or S. aureus. These vectors are commonly called “shuttle vectors".
- the vector preferably comprises one or more selectable markers such as antibiotic or heavy metal resistance.
- the Rhodococcus expression system is used to produce a polypeptide of interest.
- Rhodococcus cells are transformed with a recombinant vector which expresses the polypeptide of interest.
- the Rhodococcus cells are then cultured under conditions that allow the polypeptide to be produced, and the polypeptide is recovered form the cultured cells.
- Rhodococcus expression system is used as a vaccine.
- a nucleic acid encoding an antigen is transformed into the Rhodococcus expression system, and the transformed bacteria are used to immunize a vertebrate and thus elicit protective immunity against the antigen.
- the ability of Rhodococcus to stimulate the production of IL-12 by macrophages makes it a good candidate for the delivery of antigens when cell mediated immunity is desired. Examples of this approach which may be mentioned include the expression of M. tuberculosis antigens, M. laprae antigens, and HIV antigens in Rhodococcus, and the use of the transformed bacteria to immunize a vertebrate against tuberculosis, leprosy, or AIDS. Examples
- Avirulent organisms lacking the large virulence-associated plasmid, were developed by repeated passage of an originally virulent strain in culture. During passage in culture some of the organisms lose their plasmids.
- a plasmid-positive organism (designed herein as “103 + “ or " 103 + ”) was passaged for 50 generations in culture. The population was then plated and several colonies were picked and analyzed. A plasmid-negative isolate (designated herein as “103-” or " 103 " ”) was selected.
- the intracellular growth in macrophages of a strain of R. equi containing the large virulence-associated plasmid (103 +) was compared to the growth of the isogenic strain lacking this plasmid (103-).
- Intracellular growth of R. equi in macrophages was measured using an immunofluorescence-based assay (Hondalus and Mosser, Infect, and Immun. 62:4167-4175 (1994)). Briefly, parallel monolayers were differentially fixed with either methanol or paraformaldehyde. Methanol fixation permeabilizes the macrophage cell membrane so that both extracellular and intracellular bacteria are visible following staining, whereas paraformaldehyde fixation permits quantitation of extracellular bacteria only.
- Plasmid-positive or plasmid-negative bacteria were added to monolayers of murine macrophages for one hour. After washing, intracellular growth was measured over the next 48 hours. For each sample, 200 macrophages were counted. Bacterial growth was expressed as either the number of bacteria per 200 macrophages or the number of macrophages (out of the 200 counted) with ten or more bacteria. As shown in Figure 1, the strain containing the virulence- associated plasmid (103 + ) grew efficiently in macrophages. By 48 hours postinfection, there was an increase in the total number of intracellular bacteria associated with the monolayers and most of the infected cells contained 10 or more bacteria. In contrast to the plasmid-positive strain, the plasmid-negative strain (103-) was not able to replicate efficiently in macrophages. The two strains of bacteria exhibited similar extracellular growth kinetics in broth and on plates.
- Macrophages and Mice are the species of choice to measure virulence of R. equi
- mice were injected intravenously with equal numbers of plasmid-positive or plasmid-negative bacteria. At five days post-infection the livers and spleens were removed and the number of bacteria in each organ was quantitated by plating serial dilutions of whole organ homogenates.
- the pYUB415 plasmid is a 9301 bp mycobacterium-E. coli shuttle vector. It contains the col ⁇ l origin of replication for E. coli and the pAL5000 origin of replication for mycobacteria. It bears a bal gene encoding ampicillin resistance in E. coli and the hyg gene encoding hygromycin resistance in mycobacteria.
- a 1.6 kbp BamHl/ ⁇ coRV fragment encoding VapA was subcloned into BamHl/ ⁇ coRV- digested pYUB415.
- the pYUB415-VapA plasmid was transformed into the 103- isolate (See Example 1) of R. equi. Electroporation was performed using a Gene Pulser
- 103- strain was transformed with the pYUB415 vector alone (103 " pYUB415).
- Transformed bacteria were selected on hygromycin and analyzed for VapA expression.
- VapA protein on their surface. Bacteria were stained by indirect immunofluorescence using culture supernatants containing a monoclonal antibody (mAb 103) to VapA. As shown in Figure 3, the expression of VapA on the transformants (103 " pYUB415-VapA) was comparable to wild-type (103 +) organisms. VapA expression on transformed bacteria was stable in culture in the presence of antibiotics, as shown in Table 1.
- Table 1 shows a flow cytometry analysis on bacteria from five successive passages. There was no loss in VapA levels on the surface of transformed bacteria. VapA expression on transformed bacteria was temperature sensitive, similar to that on wildtype bacteria.
- VapA The expression of VapA was monitored by flow cytometry using an anti-VapA primary antibody and a goat anti-mouse FITC secondary antibody. As shown in Table 2, the VapA plasmid was stably expressed over seven passages even in the absence of hygromycin. These data indicate that vaccines according to the present invention can be used to express the VapA antigen in a vertebrate without the use of antibiotic selection.
- 103 + control is 103 + stained with an irrelevant IgGl isotype control antibody (Mopc21)
- the bacteria transformed with vapA were avirulent and did not grow in macrophages under conditions where the virulent strains exhibited good intracellular replication. These bacteria also failed to grow efficiently in the macrophage-like cell line J-774. This cell line has reduced microbicidal activity relative to primary macrophages, and these cells are generally very permissive to intracellular growth. Bacteria were added to J-774 cell monolayers for one hour, washed, and then examined over the next 48 hours by fluorescence microscopy. The average number of bacteria/macrophage and the number of macrophages (out of 200) with ten or more bacteria were quantitated. The vapA -transformed bacteria failed to grow efficiently in J-774 cells, as shown in Figure 4.
- mice were infected with these organisms and bacterial burdens in the livers and spleens were measured over the next week. Groups of five mice each were injected with 2-5 x 10 6 virulent 103 + bacteria or avirulent 103- bacteria that were transformed with either the 415 vector alone or with the 415 vector including the vapA gene. Spleen and liver burdens were determined at five days postinfection by a colony forming unit assay.
- the transformed organisms (bacteria transformed with vector alone or vector expressing VapA) were completely cleared from infected mice. By five days post-infection there were no viable bacteria in either the liver or spleen. At this time the virulent organisms were exhibiting peak growth. Thus, the vapA gene product alone is not sufficient to confer virulence to R. equi.
- IL-12 Production by Infected Macrophages
- RT-PCR semi-quantitative competitive reverse-transcriptase polymerase chain reaction
- IL-12 is an effective stimulator of cell-mediated immunity (CMI), which is the component of the immune system most important for the clearance of intracellular pathogens.
- CMI cell-mediated immunity
- Part of the mechanism of action of IL-12 is to induce NK cells to produce ⁇ -interferon, a molecule which activates macrophages to kill intracellular pathogens such as R. equi.
- the transcription of iNOS is a marker for macrophage activation in the murine system.
- Monolayers of resident and ⁇ -interferon primed macrophages (approx. 1 x 10 5 cells/monolayer) were incubated with increasing amounts of R. equi, ranging from 2 x 10 5 to 2.5 x 10 6 bacteria/monolayer (a ratio of 2-25 bacteria/macrophage) in the presence of serum as an opsonin to promote bacterial uptake into the macrophages.
- the RNA was reverse transcribed and the cDNA was amplified by the polymerase chain reaction along with a competitive mimic.
- the pPQRS plasmid contains a number of competitive mimic cytokines, and was provided by Dr. Steven Reiner (University of Chicago Medical School) (Reiner et al. , J. Immunol. Methods. 165:37-46 (1993)).
- a known concentration of the pPQRS plasmid was added to each reaction. The results are shown in Figure 6.
- the upper band on the gels is the competitive mimic and the lower band is the actual cDNA.
- the amount of cDNA was deduced by comparing the intensities of the upper and lower bands.
- Input cDNA was normalized to the housekeeping gene, HPRT.
- macrophages exposed to R. equi alone or R. equi plus ⁇ -interferon made detectable amounts of IL-12.
- the 238 isolate induced the production of low levels of IL-12 in resting macrophages and higher levels of IL-12 in interferon-primed macrophages.
- R. equi is therefore a potent stimulator of IL-12 even by resident (non-activated) macrophages. Similar results were obtained using avirulent (virulence associated plasmid-negative) bacteria.
- mice per group Five mice per group were vaccinated with 2 x 10 6 viable wildtype R. equi (103 +), strain 103- transformed with vector alone (103 " 415), or strain 103- transformed with a plasmid encoding VapA (103 VapA). After two weeks, mice were infected intravenously with 1 x 10 7 virulent 103 + bacteria. After five days the liver (Fig. 7 A) and spleens (Fig. 7B) were removed and the number of viable bacteria was determined by dilution plating. As shown in Figure 7, mice vaccinated with avirulent bacteria had relatively high numbers of bacteria in their livers and spleens.
- the lack of protection by the avirulent strain may be because it is either cleared too rapidly to elicit an immune response or because it lacks the appropriate stimulatory antigens, or both. Mice infected with the same number of wildtype R. equi (103 + ) cleared the majority of their bacteria, showing that mice which recover from infection with wildtype bacteria are protected from subsequent infection.
- mice vaccinated with transformed attenuated R. equi expressing recombinant VapA exhibited significant reductions in the number of bacteria in their livers and spleens, relative to mice vaccinated with avirulent bacteria.
- Mice vaccinated with avirulent bacteria transformed with vector alone contained an average of 98,480 bacteria/liver _+ 27,279 (SD).
- Mice vaccinated with avirulent bacteria expressing recombinant VapA contained an average of 16,010 bacteria/liver +_ 813 (SD). This represents an 84% reduction in the number of bacteria in the liver.
- bacteria R. equi strains 103 + , 103-, and 103-VapA
- Eight three-week old foals were infected intrabronchially with a standardized dose (approx. 1 x 10° bacteria) of a virulent strain of R. equi containing the large virulence associated plasmid and expressing VapA (103 +), eight foals were infected with the plasmid cured derivative of strain 103 (103-), and six foals received only saline (controls).
- each group half of the foals were euthanized three days post infection and half of the foals were euthanized fourteen days post infection.
- three foals were infected with avirulent 103- bacteria transformed with the Mycobacterium-E. coli 415 shuttle vector encoding VapA (103-VapA) and euthanized fourteen days post infection.
- the 103 + and 103-VapA strains expressed VapA to the same extent in vitro.
- the heart rate, respiratory rate, temperature, white blood cell count and fibrinogen concentration were monitored in the foals.
- the foals were subjected to a post-mortem examination.
- the foals infected with the 103 + strain developed significantly higher temperatures, heart rates, respiratory rates, and fibrinogen concentrations than the control groups begining nine days post infection.
- the foals infected with 103- and 103-VapA remained asymptomatic.
- the foals administered 103-, 103- VapA, or saline showed no gross lung lesions.
- all of the foals infected with 103 + had lesions ranging from mild to moderate consolidation of the cranio-ventral lung lobes on day 3 , to a severe pyogranulomatous pneumonia involving more than 60% of the lungs on day 14.
- avirulent R. equi which express VapA but do not contain antibiotic resistance markers are constructed. These organisms express VapA from a vapA gene which is integrated into the bacterial chromosome.
- the vapA gene is subcloned into a "suicide vector" containing a kanamycin resistance gene (aph) flanked by res- recombinase binding sites.
- the suicide vector can replicate in E. coli but not R. equi.
- transformation of R. equi and selection for kanamycin resistance identifies those bacteria in which the plasmid has randomly and illegitimately integrated into the chromosome. Since chromosomal location can affect gene expression, several clones are screened for VapA expression. In those clones stably expressing levels of the VapA protein approaching that of wildtype, the kanamycin resistance gene is removed.
- Removal of the antibiotic resistance marker is accomplished by transforming these clones with a replicating plasmid containing a hygromycin resistance gene and expressing the gamma-delta-resolvase.
- the resolvase binds to the res sequences and through site-specific recombination, the intervening kanamycin resistance gene is cleaved out.
- Kanamycin sensitive clones are passaged in the absence of antibiotic to encourage loss of the replicating plasmid.
- Recombinants that express VapA and are kanamycin and hygromycin sensitive are used to immunize foals as described in Example 6.
- expression vectors which can be used include CDM8 and Ap r M8, each of which comprises a CMV promoter and a multicloning site into which genes can be inserted (Moser et al. , J. Cell Biology 116:511-20 (1992); Rosenthal et al , Infection and Immunity 64:2206-15 (1996)).
- the CDM8 and ApTvI8 plasmids were provided by Dr. Tim Springer (Harvard Medical School) and Dr. Lloyd Vogelstein (formerly of Johns Hopkins Medical School) respectively.
- a DNA fragment containing the vapA gene is cloned into each plasmid.
- Recombinant plasmid DNA is isolated using standard methods.
- mice are injected in the hind muscle with approximately 100 ⁇ g of plasmid DNA containing the vapA gene.
- the direct gene transfer protocol into the tibialis anterior (TA) muscle of mice has been previously published (Davis et al. , Human Molecular Genetics 2: 1847-1851 (1993)). Briefly, 50 ⁇ g of purified plasmid DNA are injected into each of the two TA muscles, using a 27G needle. Mice are anesthetized, shaved and injected slowly with 50 ⁇ of DNA in sterile endotoxin-free saline containing 20% sucrose.
- a small piece of polyethylene tubing is fit over the needle, allowing only 2.5 mm of needle to protrude, to optimize the depth of injection.
- DNA is injected into intact muscles. Animals are examined 2-3 weeks later for antibody titres to R. equi and VapA. Some mice are treated with a single injection of Cardiotoxin (Sigma, St. Louis) seven days before the injection of DNA.
- mice are challenged with a dose of 1 x 10 7 cfu of virulent R. equi, a dose which is just below the LD50.
- a dose which is just below the LD50 is just below the LD50.
- the animals are sacrificed and the livers, lungs, and spleens are harvested. The number of viable bacteria per organ is enumerated.
- DNA For injection, about 100 ⁇ g DNA is injected into the muscle using a needle.
- the gene gun is an apparatus that injects small beads coated with DNA. Each firing of the gun injects about 0.5 mg of beads which contains approximately 0.5 ⁇ g DNA. For each immunization, the horses are anesthetized and "shot" approximately 25 times, to deliver approximately 15 ⁇ g DNA.
- vapA gene is cloned into E. co/ -mycobacterial shuttle vectors and into integrating vectors (Stover et al. , Nature 351:456-59 (1991)).
- the shuttle vector plasmid designated pMV261 was obtained from Dr. W. Jacobs and Dr. B. Bloom (Albert Einstein College of Medicine, Bronx, N.Y.). This is an extrachromosomal replicon containing an E. coli origin of replication (oriE) and the Tn903 -derived aph gene conferring kanamycin resistance for use as a selectable marker for both E. coli and mycobacteria.
- the vector also contains an origin of replication for mycobacteria.
- the vector contains an expression cassette consisting of the mycobacterial hsp60 promoter, a multiple cloning site and a transcription terminator.
- the pMV361 vector (Dr. W. Jacobs) is an integrating vector in which the oriM of pMV261 has been removed and replaced with DNA carrying the attachment site (attP) and integrase (inf) gene of mycobacteria phage L5.
- this vector can integrate into the mycobacterial chromosome via site- specific recombination.
- Vectors containing the vapA gene are transformed into mycobacteria by electroporation. Expression of the VapA protein is demonstrated using Western blot techniques.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU86046/98A AU8604698A (en) | 1997-07-28 | 1998-07-24 | Genetically engineered rhodococcus vaccine |
CA002298558A CA2298558A1 (en) | 1997-07-28 | 1998-07-24 | Genetically engineered rhodococcus vaccine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5393797P | 1997-07-28 | 1997-07-28 | |
US60/053,937 | 1997-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999005304A1 true WO1999005304A1 (en) | 1999-02-04 |
Family
ID=21987577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/015911 WO1999005304A1 (en) | 1997-07-28 | 1998-07-24 | Genetically engineered rhodococcus vaccine |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8604698A (en) |
CA (1) | CA2298558A1 (en) |
WO (1) | WO1999005304A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1276757A1 (en) * | 2000-04-27 | 2003-01-22 | University Of South Australia | ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF |
WO2003035676A1 (en) * | 2001-10-26 | 2003-05-01 | University Of South Australia | Groel chimeric protein and vaccine |
AU2003263319B2 (en) * | 2002-09-06 | 2009-07-02 | University College London | Whole bacterial cells as immune modulator |
WO2010079224A1 (en) * | 2009-01-12 | 2010-07-15 | Intervet International B.V. | Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes |
JP2011200134A (en) * | 2010-03-24 | 2011-10-13 | Mitsubishi Rayon Co Ltd | Microorganism deficient or inactive in drug-resistance gene |
US8231867B2 (en) * | 2002-06-03 | 2012-07-31 | Paralab Llc | Dietzia bacterium for treatment of disease |
CN113549642A (en) * | 2021-03-02 | 2021-10-26 | 广东体必康生物科技有限公司 | Mycobacterium tuberculosis integrated expression plasmid and application thereof |
-
1998
- 1998-07-24 WO PCT/US1998/015911 patent/WO1999005304A1/en active Application Filing
- 1998-07-24 AU AU86046/98A patent/AU8604698A/en not_active Abandoned
- 1998-07-24 CA CA002298558A patent/CA2298558A1/en not_active Abandoned
Non-Patent Citations (10)
Title |
---|
ANZAI T., ET AL.: "COMPARISON OF TRACHEAL ASPIRATION WITH OTHER TESTS FOR DIAGNOSIS OF RHODOCOCCUS EQUI PNEUMONIA IN FOALS.", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 56., no. 03/04., 16 June 1997 (1997-06-16), US, pages 335 - 345., XP002913800, ISSN: 0095-1137 * |
BECU T., POLLEDO G., GASKIN J. M.: "IMMUNOPROPHYLAXIS OF RHODOCOCCUS EQUI PNEUMONIA IN FOALS.", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 56., no. 03/04., 16 June 1997 (1997-06-16), US, pages 193 - 204., XP002913901, ISSN: 0095-1137 * |
FERNANDEZ A. S., PRESCOTT J. F., NICHOLSON V. M.: "PROTECTIVE EFFECT AGAINST RHODOCOCCUS EQUI INFECTION IN MICE OF IGG PURIFIED FROM HORSES VACCINATED WITH VIRULENCE ASSOCIATED PROTEIN (VAPA)-ENRICHED ANTIGENS.", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 56., no. 03/04., 16 June 1997 (1997-06-16), NL, pages 187 - 192., XP002913909, ISSN: 0378-1135, DOI: 10.1016/S0378-1135(97)00087-4 * |
HAITES R. E., ET AL.: "PREVALENCE OF THE VIRULENCE-ASSOCIATED GENE OF RHODOCOCCUS EQUI IN ISOLATES FROM INFECTED FOALS.", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 35., no. 06., 1 June 1997 (1997-06-01), US, pages 1642 - 1644., XP002913902, ISSN: 0095-1137 * |
HONDALUS M. K.: "PATHOGENESIS AND VIRULENCE OF RHODOCOCCUS EQUI.", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 56., no. 03/04., 16 June 1997 (1997-06-16), NL, pages 257 - 268., XP002913903, ISSN: 0378-1135, DOI: 10.1016/S0378-1135(97)00094-1 * |
NICHOLSON V. M., PRESCOTT J. F.: "RESTRICTION ENZYME ANALYSIS OF THE VIRULENCE PLASMIDS OF VAPA- POSITIVE RHODOCOCCUS EQUI STRAINS ISOLATED FROM HUMANS AND HORSES.", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 35., no. 03., 1 March 1997 (1997-03-01), US, pages 738 - 740., XP002913908, ISSN: 0095-1137 * |
PRESCOTT J. F., ET AL.: "ASSESSMENT OF THE IMMUNOGENIC POTENTIAL OF RHODOCOCCUS EQUI VIRULENCE ASSOCIATED PROTEIN (VAPA) IN MICE.", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 56., no. 03/04., 1 January 1997 (1997-01-01), NL, pages 213 - 225., XP002913905, ISSN: 0378-1135, DOI: 10.1016/S0378-1135(97)00090-4 * |
PRESCOTT J. F., ET AL.: "USE OF RHODOCOCCUS EQUI VIRULENCE-ASSOCIATED PROTEIN FOR IMMUNIZATION OF FOALS AGAINST R EQUI PNEUMONIA.", AMERICAN JOURNAL OF VETERINARY RESEARCH., AMERICAN VETERINARY MEDICINE ASSOCIATION, US, vol. 58., no. 04., 1 April 1997 (1997-04-01), US, pages 356 - 359., XP002913906, ISSN: 0002-9645 * |
SUTCLIFFE I. C.: "MACROAMPHIPHILIC CELL ENVELOPE COMPONENTS OF RHODOCOCCUS EQUI AND CLOSELY RELATED BACTERIA.", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 56., no. 03/04., 16 June 1997 (1997-06-16), NL, pages 287 - 299., XP002913904, ISSN: 0378-1135, DOI: 10.1016/S0378-1135(97)00097-7 * |
TAN C., ET AL.: "MOLECULAR CHARACTERIZATION OF A LIPID-MODIFIED VIRULENCE-ASSOCIATED PROTEIN OF RHODOCOCCUS EQUI AND ITS POTENTIAL IN PROTECTIVE IMMUNITY.", CANADIAN JOURNAL OF VETERINARY RESEARCH., CANADIAN VETERINARY MEDICAL ASSOCIATION, OTTAWA, CA, vol. 59., no. 01., 1 January 1995 (1995-01-01), CA, pages 51 - 59., XP002913907, ISSN: 0830-9000 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1276757A1 (en) * | 2000-04-27 | 2003-01-22 | University Of South Australia | ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF |
EP1276757A4 (en) * | 2000-04-27 | 2004-11-24 | Univ South Australia | ANTIGENIC PEPTIDE FRAGMENTS OF VapA PROTEIN, AND USES THEREOF |
WO2003035676A1 (en) * | 2001-10-26 | 2003-05-01 | University Of South Australia | Groel chimeric protein and vaccine |
JP2005515759A (en) * | 2001-10-26 | 2005-06-02 | ユニバーシティ オブ サウス オーストラリア | GroEL chimeric proteins and vaccines |
US8414886B2 (en) | 2002-06-03 | 2013-04-09 | Paralab Llc | Method of treating disease |
US8231867B2 (en) * | 2002-06-03 | 2012-07-31 | Paralab Llc | Dietzia bacterium for treatment of disease |
AU2003263319B2 (en) * | 2002-09-06 | 2009-07-02 | University College London | Whole bacterial cells as immune modulator |
US7579009B2 (en) | 2002-09-06 | 2009-08-25 | University College London | Whole bacterial cells as immune modulator |
JP2012515147A (en) * | 2009-01-12 | 2012-07-05 | インターベツト・インターナシヨナル・ベー・ベー | Pharmaceutical composition for protecting animals against damage resulting from infection by bacteria belonging to the group of Nocardioform actinomycetes |
WO2010079224A1 (en) * | 2009-01-12 | 2010-07-15 | Intervet International B.V. | Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes |
US8574565B2 (en) | 2009-01-12 | 2013-11-05 | Intervet International B.V. | Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes |
TWI458489B (en) * | 2009-01-12 | 2014-11-01 | Intervet Int Bv | Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes |
AU2010204269B2 (en) * | 2009-01-12 | 2015-05-07 | Intervet International B.V. | Pharmaceutical composition to protect an animal against a disorder arising from an infection with a bacterium that belongs to the group of nocardioform actinomycetes |
JP2011200134A (en) * | 2010-03-24 | 2011-10-13 | Mitsubishi Rayon Co Ltd | Microorganism deficient or inactive in drug-resistance gene |
CN113549642A (en) * | 2021-03-02 | 2021-10-26 | 广东体必康生物科技有限公司 | Mycobacterium tuberculosis integrated expression plasmid and application thereof |
CN113549642B (en) * | 2021-03-02 | 2023-03-07 | 体必康生物科技(广东)股份有限公司 | Mycobacterium tuberculosis integrated expression plasmid and application thereof |
Also Published As
Publication number | Publication date |
---|---|
AU8604698A (en) | 1999-02-16 |
CA2298558A1 (en) | 1999-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6210663B1 (en) | Methods of augmenting mucosal immunity through systemic priming and mucosal boosting | |
US8604178B2 (en) | Compositions and methods of enhancing immune responses | |
JP2012501959A (en) | Composition comprising Yersinia pestis antigen | |
CN106102768B (en) | Mycobacterial antigen compositions | |
JP2007332149A (en) | Vaccine against mycobacterial infection | |
HU211031B (en) | Method for preparation of actinobacillus pleuropneumoniae vaccine | |
JP4653934B2 (en) | Bacteriophage mediated immunization methods | |
JPH04504656A (en) | bordetella vaccine | |
WO1999005304A1 (en) | Genetically engineered rhodococcus vaccine | |
TW202206598A (en) | A vaccine against sars-cov-2 and preparation thereof | |
JPH10510984A (en) | Cell-free anti-bordetella vaccine | |
EP0352250B1 (en) | Bordetella pertussis vaccine | |
JP6401148B2 (en) | Antigens and antigen combinations | |
WO2022003155A1 (en) | A dna plasmid sars-coronavirus-2/covid-19 vaccine | |
AU2001267613B2 (en) | Adjuvant composition comprising FHA protein or fragment of FHA protein in free form | |
EP0502016B1 (en) | Novel vaccine | |
KR20010083916A (en) | Vaccine preparations containing attenuated toxin | |
US20150238590A1 (en) | Use of the salmonella spp type iii secretion proteins as a protective vaccination | |
JP4535874B2 (en) | Bacteriophage-mediated immunity against hepatitis | |
WO2020049133A1 (en) | Adenylate cyclase catalytic domain deficient bordetella strains | |
US20220098558A1 (en) | Novel pasteurella multocida strains and vaccines having hyac and nanp deletions | |
RU2455024C1 (en) | Attenuated bacteria bordetella pertussis, whooping cough agent vaccine | |
WO2002026251A1 (en) | Attenuated salmonella microorganisms comprising a mutation in the sifa gene | |
WO2022072431A1 (en) | Novel pasteurella multocida strains and vaccines having hyac and nanp deletions | |
WO2003060105A1 (en) | Defective entities and uses therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09462521 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2298558 Country of ref document: CA Ref country code: CA Ref document number: 2298558 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |